Other analysts also recently issued reports about the stock. TD Securities reissued a buy rating and set a C$12.50 price objective on shares of Knight Therapeutics in a research report on Tuesday, March 14th. Mackie downgraded shares of Knight Therapeutics from a buy rating to a hold rating and cut their price objective for the company from C$12.00 to C$10.75 in a research report on Wednesday, January 4th. CIBC lowered their target price on shares of Knight Therapeutics from C$13.00 to C$9.80 in a research note on Friday, January 13th. Finally, Scotiabank upped their target price on shares of Knight Therapeutics from C$10.00 to C$10.50 and gave the company an outperform rating in a research note on Friday, December 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Knight Therapeutics presently has an average rating of Buy and an average target price of C$11.16.
Knight Therapeutics (TSE:GUD) opened at 10.10 on Wednesday. The stock has a 50 day moving average of $10.56 and a 200 day moving average of $9.93. The stock has a market cap of $1.34 billion and a P/E ratio of 71.13. Knight Therapeutics has a 1-year low of $7.20 and a 1-year high of $11.03.
Your IP Address:
Knight Therapeutics Company Profile
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024323/knight-therapeutics-inc-gud-price-target-raised-to-c11-75-at-national-bank-financial.html
Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.